investors.molecularpartners.com
Investor Relations – Molecular PartnersMolecular Partners,Investor Relations
http://investors.molecularpartners.com/
Molecular Partners,Investor Relations
http://investors.molecularpartners.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Sunday
LOAD TIME
1.1 seconds
PAGES IN
THIS WEBSITE
13
SSL
EXTERNAL LINKS
24
SITE IP
62.164.182.200
LOAD TIME
1.08 sec
SCORE
6.2
Investor Relations – Molecular Partners | investors.molecularpartners.com Reviews
https://investors.molecularpartners.com
Molecular Partners,Investor Relations
investors.molecularpartners.com
Annual & Financial Reports – Molecular Partners
http://investors.molecularpartners.com/investor-documents/annual-reports/2015.aspx
Skip to main content. Intellectual Property for DARPins. Abicipar and multi-VEGF/PDGF DARPin. Financial Calendar and Events. Register for Email News. Intellectual Property for DARPins. Abicipar and multi-VEGF/PDGF DARPin. Annual and Financial Reports. Financial Calendar and Events. Register for Email News. Annual and Financial Reports. Annual and Financial Reports. Half Year Report 2015. Annual and Financial Reports. Financial Calendar and Events. Register for Email News.
Major Shareholders – Molecular Partners
http://investors.molecularpartners.com/corporate-governance/major-shareholders.aspx
Skip to main content. Intellectual Property for DARPins. Abicipar and multi-VEGF/PDGF DARPin. Financial Calendar and Events. Register for Email News. Intellectual Property for DARPins. Abicipar and multi-VEGF/PDGF DARPin. Annual and Financial Reports. Financial Calendar and Events. Register for Email News. The complete list of disclosure notifications of shareholdings according to Art. 20 Stock Exchange Act (SESTA) can be obtained at the SIX Swiss Exchange website. Financial Calendar and Events.
Additional Share Information – Molecular Partners
http://investors.molecularpartners.com/share-information/additional-share-information.aspx
Skip to main content. Intellectual Property for DARPins. Abicipar and multi-VEGF/PDGF DARPin. Financial Calendar and Events. Register for Email News. Intellectual Property for DARPins. Abicipar and multi-VEGF/PDGF DARPin. Annual and Financial Reports. Financial Calendar and Events. Register for Email News. Since 5 November 2014, Molecular Partners is listed on the Main Standard of the SIX Swiss Exchange. SIX Swiss Exchange (Main Standard). Financial Calendar and Events. Register for Email News.
Other Information – Molecular Partners
http://investors.molecularpartners.com/share-information/other-information.aspx
Skip to main content. Intellectual Property for DARPins. Abicipar and multi-VEGF/PDGF DARPin. Financial Calendar and Events. Register for Email News. Intellectual Property for DARPins. Abicipar and multi-VEGF/PDGF DARPin. Annual and Financial Reports. Financial Calendar and Events. Register for Email News. Reporting of Stabilization Transactions. Financial Calendar and Events. Register for Email News.
Share Price Centre – Molecular Partners
http://investors.molecularpartners.com/share-information.aspx
Skip to main content. Intellectual Property for DARPins. Abicipar and multi-VEGF/PDGF DARPin. Financial Calendar and Events. Register for Email News. Intellectual Property for DARPins. Abicipar and multi-VEGF/PDGF DARPin. Annual and Financial Reports. Financial Calendar and Events. Register for Email News. Financial Calendar and Events. Register for Email News.
TOTAL PAGES IN THIS WEBSITE
13
Intellectual Property for DARPins - Molecular Partners
http://www.molecularpartners.com/aboutdarpins/intellectual-property-for-darpins
Intellectual Property for DARPins. Abicipar and multi-VEGF/PDGF DARPin. Intellectual Property for DARPins. Abicipar and multi-VEGF/PDGF DARPin. INTELLECTUAL PROPERTY OF DARPins. Intellectual Property for DARPins. Molecular Partners is a clinical-stage biopharmaceutical company working to advance modern medicine and significantly improve the management of serious diseases. We are developing a powerful new class of potent, specific and versatile small protein therapies called DARPins.
Partners - Molecular Partners
http://www.molecularpartners.com/partners
Intellectual Property for DARPins. Abicipar and multi-VEGF/PDGF DARPin. Intellectual Property for DARPins. Abicipar and multi-VEGF/PDGF DARPin. We work with leading pharmaceutical companies. Molecular Partners initiated an agreement with Janssen Biotech in 2011 to develop immunology therapies. As part of an innovative agreement, Molecular Partners will receive upfront fees, license payments and research funding as well as development and sales milestones of up to $190 million for each product. Molecular ...
Clinical Trials - Molecular Partners
http://www.molecularpartners.com/our-products/clinical-trials
Intellectual Property for DARPins. Abicipar and multi-VEGF/PDGF DARPin. Intellectual Property for DARPins. Abicipar and multi-VEGF/PDGF DARPin. For more information on any clinical trials of our investigational therapies, please visit the U.S and the EU Clinical Trials Register:.
Our Products - Molecular Partners
http://www.molecularpartners.com/our-products
Intellectual Property for DARPins. Abicipar and multi-VEGF/PDGF DARPin. Intellectual Property for DARPins. Abicipar and multi-VEGF/PDGF DARPin. Our broad pipeline addresses high value end markets (click image to enlarge). Molecular Partners has a strong focus on creating differentiated therapies for retinal diseases including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), two diseases leading to loss of vision. 8220;Despite the fact that there are well-recognized treatme...
Careers - Molecular Partners
http://www.molecularpartners.com/careers
Intellectual Property for DARPins. Abicipar and multi-VEGF/PDGF DARPin. Intellectual Property for DARPins. Abicipar and multi-VEGF/PDGF DARPin. Working at Molecular Partners. Are you a team player, whose scientific curiosity is complemented by an entrepreneurial spirit, focus and persistence? Do you feel motivated to bring innovative medical solutions to the breakthrough? Zurich has a humid continental climate with four distinct seasons. It is renowned for the natural beauty of the surrounding lakes,...
Abicipar and multi-VEGF/PDGF DARPin - Molecular Partners
http://www.molecularpartners.com/our-products/abiciparandmulti-vegf_pdgf
Intellectual Property for DARPins. Abicipar and multi-VEGF/PDGF DARPin. Intellectual Property for DARPins. Abicipar and multi-VEGF/PDGF DARPin. Abicipar and multi-VEGF/PDGF DARPin. Abicipar and multi-VEGF/PDGF DARPin. Abicipar is a DARPin-based anti-angiogenic drug for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Wet AMD is a leading cause of blindness in the developed world and DME is a leading cause of blindness in young adults in developed countries. In Phase 1/2 cl...
Actavis confirms timeline for the start of phase III development of abicipar - Molecular Partners
http://www.molecularpartners.com/2015-mp-ad-hoc-release
Intellectual Property for DARPins. Abicipar and multi-VEGF/PDGF DARPin. Intellectual Property for DARPins. Abicipar and multi-VEGF/PDGF DARPin. Actavis confirms timeline for the start of phase III development of abicipar. May 11, 2015. Zurich-Schlieren, May 11, 2015. This is the first official announcement from Actavis/Allergan on abicipar following the companies’ merger in March, underlining the commitment to the DARPin program and to the timeline proposed by Allergan prior to the merger. Molecular Part...
TOTAL LINKS TO THIS WEBSITE
24
Investor Relations | Mistras Group, Inc.
Skip to main navigation. Mar 29, 2018 11:19 AM EDT. Financial Info and Reports. We are a leading global provider of technology-enabled asset protection solutions used to evaluate the structural integrity of critical energy, industrial and public infrastructure. We operate over 100 offices worldwide, with our corporate headquarters located in Princeton Junction, New Jersey - USA. Mar 13, 2018. Fiscal 2017 Q4 and Year End Earnings Call. View all events and presentations . MISTRAS 2016 Stub Period Report.
Mitek Systems, Inc. - Investor Relations
View our LinkedIn Profile. Subscribe to our Twitter Feed. Visit us on Facebook. Visit us on Google. Visit us on YouTube. View all ». Jul 29, 2015. Mitek to Present at the Needham Interconnect Conference. Jul 23, 2015. Mitek Reports Third Quarter Fiscal 2015 Financial Results. Jul 16, 2015. Mitek to Report Third Quarter Fiscal 2015 Financial Results on July 23, 2015. Jun 17, 2015. Video Release - Mitek Completes Acquisition of IDchecker. Stock Quote and Chart. Board of Directors/Advisory Board.
Home - Mithra Pharmaceuticals Investors Website
00,00 ( 0%). Mithra’s North American Advisory Board for Donesta Will Meet in Miami, Florida the 20th- 21st January 2017. Mithra Announces 2017 Financial Calendar. View all Press Releases. Annual Report 2016 (available online). Ordinary General Shareholders’ Meeting. Half Year 2017 Results. Phone: 32 (0)4 349 28 22. Fax: 32 (0)4 349 28 21.
Welcome to Moberg Pharma | Moberg Pharma
Welcome to Moberg Pharma. No front page content has been created yet. I samarbete med Alert IR.
Technip- Investor Relations - Relations Investisseurs mobile
Bienvenue sur la version Mobile du site Relations Investisseurs de Technip. Cours de bourse mobile. Retour tête de page.
investors.molecularpartners.com
Investor Relations – Molecular Partners
Skip to main content. Intellectual Property for DARPins. Abicipar and multi-VEGF/PDGF DARPin. Financial Calendar and Events. Register for Email News. Intellectual Property for DARPins. Abicipar and multi-VEGF/PDGF DARPin. Financial Calendar and Events. Register for Email News. Molecular Partners confirms its focus on proprietary oncology pipeline discovery alliance with Roche discontinued. Allergan strengthens DARPin development and discovery alliance with Molecular Partners. 41 44 755 7700.
We're sorry -- An Error Occurred
We're sorry - An Error Occurred. The website is experiencing a temporary problem. Please try again later.
Welcome to shareholders.morningstar.com
Welcome to shareholders.morningstar.com!
Press Releases | Motorcar Parts of America, Inc.
Skip to main navigation. Motorcar Parts of America. Hub Assemblies and Bearings. Call Before You Return. Merchandising and Category Management. What's new and what we are up to. Mar 5, 2018. Motorcar Parts of America to Present at 30th Annual Roth Conference. Feb 9, 2018. Motorcar Parts of America Reports Fiscal 2018 Third Quarter Results. Feb 2, 2018. Motorcar Parts of America to Report Fiscal 2018 Third Quarter Results; Host Conference Call. LOS ANGELES , Feb. 02, 2018 (GLOBE NEWSWIRE) - Motorcar P...
investors.motorolasolutions.com
Investor Relations - Motorola Solutions USA
Earnings and SEC Filings. 134 ( 1.29%). Minimum 20 minute delay. 2018 Motorola Solutions Financial Analyst Meeting. February 27, 2018 - 1:00 - 4:00 PM CT. MOTOROLA SOLUTIONS COMPLETES ACQUISITION OF AVIGILON. Q4 2017 MOTOROLA SOLUTIONS EARNINGS CONFERENCE CALL. February 1, 2018 - 4:00 PM CT. MOTOROLA SOLUTIONS AND FIRSTNET. Motorola Solutions is pleased to be a key player in the team selected by FirstNet to build the U.S. nationwide public safety broadband network. Earnings and SEC Filings. Market Cap ( $.
Investor Relations | MSA | United States
Fall Protection Equipment MSA United States. Fixed Gas and Flame Detection. Supplied Air Respirators (SCBA). MSA Declares Third Quarter Dividend. MSA Announces Second Quarter Results. MSA Schedules Second Quarter Earnings Webcast. There are currently no events scheduled. Sign up to receive email alerts whenever MSA Safety Incorporated posts new information to the site. Just enter your email address and click Submit. Minimum 20 minutes delayed. Dividend and Split History. Q2 2015 Earnings Press Release.
